Dr. Hervé Jacquiau focuses his legal practice in the areas of Intellectual Property, Business Development and Research & Development. Formerly a patent agent and technical advisor with the firm, Hervé has years of experience involving patent prosecution and litigation.

His background covers a variety of technologies, particularly biotechnology (e.g. biofuels, fermentation processes); chemical engineering, molecular pharmacology and biochemistry (e.g. pharmaceuticals, biosimilars); cell biology, genetics and microbiology (e.g. biosensors, medical research, oncology); food and biology industries (e.g. wine, antibiotics and antibody production).

Before receiving his law degree, Hervé received his Ph.D. from the University of Cambridge after investigating the genetic and biochemical features responsible for the biodegradation of toxic pollutants. He developed novel genetic tools to develop biosensors and became co-inventor (U.S. Patent No. 6,849,442). His work contributed to the creation of a biotechnology company that specializes in developing biosensors for the detection and removal of environmental contaminants.

As a postdoctoral research associate at St. Jude Children’s Research Hospital, Hervé investigated various mechanisms that regulate cellular sensitivity or resistance to anti-cancer agents. He investigated DNA rearrangements and cell-cycle regulation and highlighted the role of various mechanisms of protein degradation in modulating cellular response to enzyme inhibitors that are commonly used in the treatment of childhood cancer.

Hervé previously worked at the Lankenau Institute for Medical Research (LIMR), where he conducted translational research and developed antibodies to be used in cancer diagnostics or research tools. At the institute, Hervé evaluated scientific innovations and business proposals to develop IP strategies and to expand LIMR’s biotechnology incubators. He subsequently became a business and scientific funding associate in the Department of Business Development.

Hervé contributed to the creation of a novel drug screening facility for drug target validation and drug discovery, as well as a center for the production of human antibodies to be used as medical diagnostics or as novel therapeutics. He collaborated with surgeons and clinicians to develop protocols for clinical trials. Hervé also wrote proposals to attract funding and to promote scientific collaborations.

Earlier in his career, Hervé earned a master of science degree in bioreactor systems and biotechnology. As an undergraduate, he studied biological sciences, as well as the food and biological industries.

• Hahn Loeser & Parks LLP Moves Chicago Office to New Space to Allow for Continued Expansion
  September 20, 2019
• Hahn Loeser’s Hervé Jacquiau Passes Bar Exam; Adds Depth to Chicago Office
  November 08, 2018

• Author

  “Defects in SUMO Conjugation and DeSUMOylation Alter Cell Sensitivity to DNA Topoisomerase I-induced DNA Damage”

  June 24, 2005
• Author

  Biosensor Materials and Methods – U.S. Patent

  February 01, 2005
• Author

  “SUMO Conjugation and Proteolysis Regulate Cell Sensitivity to DNA Topoisomerase I Levels and Poisons

  April 01, 2004
• Author

  “The DNA Replication Licensing Factor Tah11 (Cdt1) Functions to Protect Cells From Camptothecin and Replication Fork Arrest”

  April 01, 2004
• Author

  “The Deubiquitinating Enzyme Doa4p Protects Cells from DNA Topoisomerase I Poisons”

  February 26, 2004
• Author

  “Alterations in the SUMO-Conjugating Enzyme UBC9 Distinguish Enzyme Functions Essential for Cell Viability and Responses to DNA Damage

  March 03, 2003
• Author

  “Yeast as a Model System in the Analysis of DNA Topoisomerase I Poisons”

  January 01, 2003
• Author

  “Ubiquitin-Mediated Proteolysis and Cell Sensitivity to Camptothecin”

  March 01, 2002